Fulvestrant for the Treatment of Pulmonary Arterial Hypertension.
作者信息
Kawut Steven M, Pinder Diane, Al-Naamani Nadine, McCormick Amber, Palevsky Harold I, Fritz Jason, Smith K Akaya, Mazurek Jeremy A, Doyle Margaret F, MacLean Margaret R, DeMichele Angela, Mankoff David A
机构信息
Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, Pennsylvania.
University of VermontBurlington, Vermontand.
出版信息
Ann Am Thorac Soc. 2019 Nov;16(11):1456-1459. doi: 10.1513/AnnalsATS.201904-328RL.
Abstract
摘要
相似文献
1
Fulvestrant for the Treatment of Pulmonary Arterial Hypertension.氟维司群用于治疗肺动脉高压
Ann Am Thorac Soc. 2019 Nov;16(11):1456-1459. doi: 10.1513/AnnalsATS.201904-328RL.
2
Fulvestrant plus anastrozole for metastatic breast cancer.氟维司群联合阿那曲唑治疗转移性乳腺癌。
Lancet Oncol. 2019 May;20(5):e247. doi: 10.1016/S1470-2045(19)30217-7. Epub 2019 Apr 4.
3
Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study).500毫克氟维司群用于既往接受内分泌治疗的绝经后日本雌激素受体阳性晚期或复发性乳腺癌患者的多中心观察性研究（SBCCSG29研究）
J Nippon Med Sch. 2019;86(3):165-171. doi: 10.1272/jnms.JNMS.2019_86-305.
4
Abemaciclib plus fulvestrant for breast cancer.阿贝西利联合氟维司群治疗乳腺癌。
Lancet Oncol. 2019 Nov;20(11):e617. doi: 10.1016/S1470-2045(19)30629-1. Epub 2019 Oct 3.
5
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.阿贝西利联合曲妥珠单抗和（或）氟维司群对比曲妥珠单抗联合标准治疗化疗用于激素受体阳性、HER2 阳性晚期乳腺癌患者（monarcHER）：一项随机、开放标签、二期临床试验。
Lancet Oncol. 2020 Jun;21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1. Epub 2020 Apr 27.
6
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.阿培利司联合氟维司群治疗 PI3KCA 突变型和野生型雌激素受体阳性晚期乳腺癌：一项 Ib 期临床试验。
JAMA Oncol. 2019 Feb 1;5(2):e184475. doi: 10.1001/jamaoncol.2018.4475. Epub 2019 Feb 14.
7
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.氟维司群联合阿那曲唑治疗转移性乳腺癌的总生存期。
N Engl J Med. 2019 Mar 28;380(13):1226-1234. doi: 10.1056/NEJMoa1811714.
8
Fulvestrant-induced toxic epidermal necrolysis.氟维司群诱导的中毒性表皮坏死松解症。
An Bras Dermatol. 2019 Mar-Apr;94(2):218-220. doi: 10.1590/abd1806-4841.20197964. Epub 2019 May 9.
9
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.氟维司群 500mg 对比其他内分泌治疗药物用于激素受体阳性晚期乳腺癌的临床获益率的荟萃分析。
Breast Cancer. 2019 Nov;26(6):703-711. doi: 10.1007/s12282-019-00973-4. Epub 2019 May 11.
10
Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant.转移性乳腺癌患者在接受氟维司群治疗前应区分有肺或肝转移。
Cancer Med. 2019 Oct;8(14):6212-6220. doi: 10.1002/cam4.2453. Epub 2019 Aug 2.
引用本文的文献
1
Sex differences in pulmonary (arterial) hypertension: does it matter?肺动脉高压中的性别差异：这重要吗？
Curr Opin Pulm Med. 2025 Sep 1;31(5):411-428. doi: 10.1097/MCP.0000000000001197. Epub 2025 Jul 23.
2
Decoding the enigmatic estrogen paradox in pulmonary hypertension: delving into estrogen metabolites and metabolic enzymes.解读肺动脉高压中神秘的雌激素悖论：深入探究雌激素代谢产物和代谢酶
Cell Mol Biol Lett. 2024 Dec 18;29(1):155. doi: 10.1186/s11658-024-00671-w.
3
Pulmonary Hypertension and Hyperglycemia-Not a Sweet Combination.肺动脉高压与高血糖——并非甜蜜组合。
Diagnostics (Basel). 2024 May 28;14(11):1119. doi: 10.3390/diagnostics14111119.
4
Behavior of Hypertrophied Right Ventricle during the Development of Left Ventricular Failure Due to Myocardial Infarction.心肌梗死致左心室衰竭发展过程中肥厚右心室的行为表现。
Int J Mol Sci. 2024 Feb 23;25(5):2610. doi: 10.3390/ijms25052610.
5
A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension.肺动脉高压新型治疗方法的系统评价。
Am J Cardiovasc Drugs. 2024 Jan;24(1):39-54. doi: 10.1007/s40256-023-00613-5. Epub 2023 Nov 9.
6
Sex-biased TGFβ signalling in pulmonary arterial hypertension.肺动脉高压中的性别偏倚 TGFβ 信号传导。
Cardiovasc Res. 2023 Oct 24;119(13):2262-2277. doi: 10.1093/cvr/cvad129.
7
SOX17 Deficiency Mediates Pulmonary Hypertension: At the Crossroads of Sex, Metabolism, and Genetics.SOX17 缺乏介导肺动脉高压：性别、代谢和遗传的十字路口。
Am J Respir Crit Care Med. 2023 Apr 15;207(8):1055-1069. doi: 10.1164/rccm.202203-0450OC.
8
A pilot study to examine association of BMI with functional class and 6 min walk distance in idiopathic and heritable PAH: Possible association with estrogen metabolism.一项关于特发性和遗传性肺动脉高压中BMI与功能分级及6分钟步行距离之间关联的初步研究：与雌激素代谢的可能关联。
Pulm Circ. 2022 Jul 1;12(3):e12139. doi: 10.1002/pul2.12139. eCollection 2022 Jul.
9
Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials.肺动脉高压随机临床试验中的基线性别差异。
Ann Am Thorac Soc. 2023 Jan;20(1):58-66. doi: 10.1513/AnnalsATS.202203-207OC.
10
Sex Differences in Pulmonary Hypertension.肺动脉高压中的性别差异
Front Aging. 2021 Oct 4;2:727558. doi: 10.3389/fragi.2021.727558. eCollection 2021.
本文引用的文献
1
Role of the Aryl Hydrocarbon Receptor/ARNT/Cytochrome P450 System in Pulmonary Vascular Diseases.芳香烃受体/芳香烃受体核转位蛋白/细胞色素 P450 系统在肺血管疾病中的作用。
Circ Res. 2019 Jul 19;125(3):356-366. doi: 10.1161/CIRCRESAHA.119.315054. Epub 2019 Jun 26.
2
Derivatization enhances analysis of estrogens and their bioactive metabolites in human plasma by liquid chromatography tandem mass spectrometry.衍生化增强了液相色谱串联质谱法分析人血浆中的雌激素及其生物活性代谢物。
Anal Chim Acta. 2019 Apr 25;1054:84-94. doi: 10.1016/j.aca.2018.12.023. Epub 2018 Dec 21.
3
Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension.DHEA-S 水平较低预示着特发性、结缔组织疾病相关性和先天性心脏病相关性肺动脉高压的绝经后女性发生疾病和不良结局。
Eur Respir J. 2018 Jun 28;51(6). doi: 10.1183/13993003.00467-2018. Print 2018 Jun.
4
Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.雌激素抑制可逆转肺动脉高压和相关代谢缺陷。
Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.02337-2016. Print 2017 Aug.
5
Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial.阿那曲唑治疗肺动脉高压：一项随机、双盲、安慰剂对照试验
Am J Respir Crit Care Med. 2017 Feb 1;195(3):360-368. doi: 10.1164/rccm.201605-1024OC.
6
18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.18F-氟雌二醇正电子发射断层扫描：现状与未来潜在临床应用
J Nucl Med. 2016 Aug;57(8):1269-75. doi: 10.2967/jnumed.116.175596. Epub 2016 Jun 15.
7
Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men.较高的雌二醇水平和较低的硫酸脱氢表雄酮水平与男性肺动脉高压相关。
Am J Respir Crit Care Med. 2016 May 15;193(10):1168-75. doi: 10.1164/rccm.201509-1785OC.
8
Estrogen Metabolite 16α-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism.雌激素代谢物16α-羟基雌酮通过微小RNA-29介导的细胞代谢调节加重II型骨形态发生蛋白受体相关的肺动脉高压。
Circulation. 2016 Jan 5;133(1):82-97. doi: 10.1161/CIRCULATIONAHA.115.016133. Epub 2015 Oct 20.
9
Oestrogen receptor alpha in pulmonary hypertension.肺动脉高压中的雌激素受体α
Cardiovasc Res. 2015 May 1;106(2):206-16. doi: 10.1093/cvr/cvv106. Epub 2015 Mar 12.
10
Biology and flow cytometry of proangiogenic hematopoietic progenitors cells.促血管生成造血祖细胞的生物学特性与流式细胞术
Cytometry A. 2015 Jan;87(1):5-19. doi: 10.1002/cyto.a.22596. Epub 2014 Nov 21.
Zotero 插件